GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (NAS:IVA) » Definitions » Total Stockholders Equity

Inventiva (Inventiva) Total Stockholders Equity : $-34.93 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Inventiva Total Stockholders Equity?

Inventiva's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-34.93 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Inventiva's Book Value per Share for the quarter that ended in Dec. 2023 was $-0.67. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Inventiva's Debt-to-Equity for the quarter that ended in Dec. 2023 was -1.17.

Inventiva Total Stockholders Equity Historical Data

The historical data trend for Inventiva's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventiva Total Stockholders Equity Chart

Inventiva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.99 135.29 100.42 48.17 -34.93

Inventiva Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.42 73.71 48.17 -8.31 -34.93

Inventiva  (NAS:IVA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Inventiva's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-34.93-0)/52.1158
=-0.67

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Inventiva's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(5.788 + 35.094) / -34.93
=-1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Inventiva's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Inventiva (Inventiva) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (NAS:IVA) » Definitions » Total Stockholders Equity
Comparable Companies
XPAR:AELIS XPAR:IPH XPAR:DBV XPAR:MEDCL XPAR:NANO XPAR:GNFT XPAR:TNG XPAR:ALSEN XPAR:ADOC XPAR:OSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IVA:France 6IV:Germany
Address
50 rue de Dijon, Daix, FRA, 21121
Website
https://www.inventivapharma.com
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.